YCBD Stock Risk & Deep Value Analysis

cbdMD Inc

Healthcare • Drug Manufacturers - Specialty & Generic

DVR Score

0.5

out of 10

Distressed

What You Need to Know About YCBD Stock

We analyzed cbdMD Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran YCBD through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.

Updated Mar 2, 2026•Run Fresh Analysis →

How Risky Is YCBD Stock?

Overall Risk

Aggressive

Financial Risk

High

Market Risk

High

Competitive Risk

High

Execution Risk

High

Regulatory Risk

High

What Are the Red Flags for YCBD?

  • âš 

    Continued negative cash flow and depletion of cash reserves

  • âš 

    Further highly dilutive equity offerings

  • âš 

    Increased competitive pressure from well-funded rivals

  • âš 

    Failure to meet listing requirements (potential delisting)

Unlock YCBD Red Flags & Risk Warnings

Create a free account to see the full analysis

What Does cbdMD Inc (YCBD) Do?

Market Cap

$9.28M

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

42

cbdMD, Inc. produces and distributes various cannabidiol (CBD) products in the United States. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, hempMD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, drink mixes, ready to drink cans, and sleep, focus, and calming aids. It also provides veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name; nootropic mushroom line under the ATRx brand; and hemp derived solutions under the hempMD brand. It distributes its products through its e-commerce website, third-party e-commerce sites, select distributors and marketing partners, wholesalers, and various brick and mortar retailers. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. is headquartered in Charlotte, North Carolina.

Visit cbdMD Inc Website

Is YCBD Stock Undervalued?

cbdMD, Inc. (YCBD) continues to represent an extremely high-risk, speculative investment with very limited 10x growth potential within 3-5 years. The $10M market cap (as of previous analysis, likely similar) still indicates severe financial distress, precarious operations, and ongoing struggles with competitive differentiation and profitability. No material positive changes have been publicly signaled or are realistically expected within the short 42-day period since the last review. The company faces persistent cash burn, significant industry headwinds, and intense competition. While the CBD market offers a TAM, YCBD's ability to capture meaningful, profitable share remains highly questionable, relegating any upside to highly improbable events like a sudden regulatory shift or an unexpected acquisition, which are not currently supported by fundamentals or market positioning.

Unlock the full AI analysis for YCBD

Get the complete DVR score, risk analysis, and more

Is YCBD Financially Healthy?

P/E Ratio

2.04

Does YCBD Have a Competitive Moat?

Sign in to unlock

Moat Rating

⚪ None

Moat Trend

Eroding

The company possesses no identifiable sustainable competitive advantages. Its brand power is weak, intellectual property is not distinctive enough to create a barrier, and it lacks cost advantages or efficient scale in a highly commoditized market.

Moat Erosion Risks

  • •Intense price competition from numerous brands and private labels.
  • •Lack of proprietary technology or unique product differentiation.
  • •Limited financial resources to invest in brand building or R&D.

YCBD Competitive Moat Analysis

Sign up to see competitive advantages

What Could Drive YCBD Stock Higher?

Near-Term (0-6 months)

  • •Q1 2026 Earnings Report (estimated late March/early April 2026)
  • •Potential minor product line expansion (e.g., new cannabinoid offering)

Medium-Term (6-18 months)

  • •Increased strategic partnerships with retailers or distributors (unconfirmed)
  • •Small-scale market expansion within existing regulatory frameworks

Long-Term (18+ months)

  • •Federal legalization of cannabis/CBD leading to broader market acceptance
  • •Significant industry consolidation resulting in an acquisition of YCBD

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

What's the Bull Case for YCBD?

  • ✓

    Reported path to sustained positive cash flow and profitability

  • ✓

    Significant debt reduction or successful, non-dilutive capital raise

  • ✓

    Announcement of major, value-accretive strategic partnerships

Bull Case Analysis

See what could go right with Premium

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for YCBD (cbdMD Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.

More Resources to Boost Your Portfolio

Explore our other guides and tools to maximize your investment returns

5-Minute Guide Thumbnail

6 Simple Steps Spotting Undervalued Stocks

Learn More
Dividend Stocks Thumbnail

Earn $500/Month with Dividend Stocks

Learn More
Swing Trading Guide Thumbnail

3 Swing Trading Strategies for Predictable Gains

Learn More
Navigated to YCBD Stock Risk & Deep Value Analysis